Modification of a natural product with antibiotic properties to block its efflux from Mycobacterium tuberculosis results in a new drug candidate for tuberculosis with a promising therapeutic profile in mice (pages 152–158).
References
Nathan, C. Sci. Transl. Med. 4, 140sr2 (2012).
Nathan, C. Nature 431, 899–902 (2004).
Lee, R.E. et al. Nat. Med. 20, 152–158 (2014).
Spellberg, B., Bartlett, J.G. & Gilbert, D.N. N. Engl. J. Med. 368, 299–302 (2013).
Bolan, G.A., Sparling, P.F. & Wasserheit, J.N. N. Engl. J. Med. 366, 485–487 (2012).
Raviglione, M. et al. Lancet 379, 1902–1913 (2012).
Ahuja, S.D. et al. PLoS Med. 9, e1001300 (2012).
Tiemersma, E.W., van der Werf, M.J., Borgdorff, M.W., Williams, B.G. & Nagelkerke, N.J. PLoS ONE 6, e17601 (2011).
Avorn, J. J. Am. Med. Assoc. 309, 1349–1350 (2013).
Chakraborty, S., Gruber, T., Barry, C.E. III, Boshoff, H.I. & Rhee, K.Y. Science 339, 88–91 (2013).
Prideaux, B. et al. Anal. Chem. 83, 2112–2118 (2011).
Mukamolova, G.V., Turapov, O., Malkin, J., Woltmann, G. & Barer, M.R. Am. J. Respir. Crit. Care Med. 181, 174–180 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Nathan, C. Drug-resistant tuberculosis: a new shot on goal. Nat Med 20, 121–123 (2014). https://doi.org/10.1038/nm.3470
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3470
- Springer Nature America, Inc.
This article is cited by
-
QSAR based therapeutic management of M. tuberculosis
Archives of Pharmacal Research (2017)
-
Rational design, synthesis and evaluation of novel-substituted 1,2,3-triazolylmethyl carbazoles as potent inhibitors of Mycobacterium tuberculosis
Medicinal Chemistry Research (2015)